Cardiovascular diseases are the leading cause of death globally, claiming the lives of17.9 millionpeople each year.
CardiaTec aims to address this knowledge gap with a drug discovery platform that leveragesAIto analyse human tissue multi-omics data.
These include the genome, the transcriptome, the proteome, and the epigenome.
It’s free, every week, in your inbox.
CardiaTecs technology uses computational methods to identify and prioritise dysregulated drug targets and pathways associated with the disease.
CardiaTec is also building the first and largest human heart tissue multi-omics dataset.
To do this, it has established a web link of 65 hospitals across the UK and the US.
We have identified our first therapeutic targets, Peralta said.
California-based Montage Ventures led the companys new seed round.
Peralta founded CardiaTech in 2021, alongside Namshik Han (CTO) and Thelma Zablocki (COO).
The trio spun it out from the Han Lab at the University of Cambridge.
Story byIoanna Lykiardopoulou
Ioanna is a writer at TNW.
With a background in the humanities, she has a soft spot for social impact-enabling technologies.
